A current understanding of ocular immune privilege

Current Immunology Reviews

Volumn 7, Issue 3, 2011, Pages 336-343

  Stein Streilein, Joan ^a   Lucas, Kenyatta ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Immune homeostasis; Immune privilege; T regulatory cells; Tolerance

Indexed keywords

ALPHA INTERMEDIN; CALCITONIN GENE RELATED PEPTIDE; CD200 ANTIGEN; CD200 RECEPTOR; ENDOTOXIN; INTERLEUKIN 1; NEUROPEPTIDE Y; PIGMENT EPITHELIUM DERIVED FACTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROOPIOMELANOCORTIN; SOMATOSTATIN; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

APOPTOSIS; AUTOIMMUNE DISEASE; CELL MEMBRANE; CLONAL ANERGY; EYE; EYE PROTECTION; FEVER; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGY; IMMUNOREGULATION; INFLAMMATION; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; UVEITIS;

EID: 79959929553     PISSN: 15733955     EISSN: 1875631X     Source Type: Journal    
DOI: 10.2174/157339511796196683     Document Type: Review

References (117)

1. Matsubara M, Tanishima T. Wound-healing of corneal endothelium in monkey: an autoradiographic study. Jpn J Ophthalmol 1983; 27(3): 444-50.
2. Streilein JW. Regional immunity and ocular immune privilege. Chem Immunol 1999; 73: 11-38.
3. Niederkorn JY. Regulatory T cells and the eye. Chem Immunol Allergy 2007; 92: 131-9.
4. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003; 3: 878-89.
5. van Dooremaal, 358-373 (1873). J. C. Die Entwicklung der in fremden Grund verstzten lebenden Geweba. Albrecht Fon Graefes Arch Ophthalmol [research] 1873; 19: 358-73.
6. Medawar PB. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue and to the anterior chamber of the eye. Br J Exp Pathol 1948; 29: 58-69.
7. Medawar PB. Immunity to homologous grafted skin. The fate of skin homografts transplanted to the brain, to subcutaneous tissue and to the anterior chamber of the eye. Br J Exp Pathol 1948; (29): 58-69.
8. Egan RM, Yorkey C, Black R, et al. In vivo behavior of peptidespecific T cells during mucosal tolerance induction: antigen introduced through the mucosa of the conjunctiva elicits prolonged antigen-specific T cell priming followed by anergy. J Immunol 2000; 164(9): 4543-50.
9. Plskova J, Duncan L, Holan V, Filipec M, Kraal G, Forrester JV. The immune response to corneal allograft requires a site-specific draining lymph node. Transplantation 2002; 73(2): 210-5.
10. Xu H, Manivannan A, Crane I, Dawson R, Liversidge J. Critical but divergent roles for CD62L and CD44 in directing blood monocyte trafficking in vivo during inflammation. Blood 2008; 112(4): 1166-74.
11. Forrester JV. Privilege revisited: an evaluation of the eye's defence mechanisms. Eye 2009; 23: 756-66.
12. Cursiefen C. Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy 2007; 92: 50-7.
13. Niederkorn JY. Immune privilege in the anterior chamber of the eye. Crit Rev Immunol 2002; 22(1): 13-46.
14. Crane IJ, Liversidge J. Mechanisms of leukocyte migration across the blood-retina barrier. Semin Immunopathol 2008; 30(2): 165-77.
15. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 1991; 32: 2201-11.
16. Taylor AW, Alard P, Yee DG, Streilein JW. Aqueous humor induces transforming growth factor-beta (TGF-beta)-producing regulatory T-cells. Curr Eye Res 1997; 16(9): 900-8.
17. Zamiri P, Masli S, Streilein JW, Taylor AW. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci 2006; 47(9): 3912-8.
18. Taylor AW. Ocular immunosuppressive microenvironment. Chem Immunol Allergy 2007; 92: 71-85.
19. Taylor AW, Streilein JW, Cousins SW. Identification of alphamelanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res 1992; 11: 1199-206.
20. Taylor AW, Kitaichi N, Taylor AW. Melanocortin 5 Receptor and Ocular Immunity. Cell Mol Biol 2006; 52: 141-7.
21. Lee TH, Lerner AB, Buettner-Janusch V. The isolation and structure of alpha- and beta-melanocyte-stimulating hormones from monkey pituitary glands. J Biol Chem 1961; 236: 1390-4.
22. Watanabe T, Hiltz ME, Catania A, Lipton JM. Inhibition of IL-1 beta-induced peripheral inflammation by peripheral and central administration of analogs of the neuropeptide alpha-MSH. Brain Res Bull 1993; 32(3): 311-4.
23. Holdeman M, Khorram O, Samson WK, Lipton JM. Fever-specific changes in central MSH and CRF concentrations. Am J Physiol 1985; 248(1 Pt 2): R125-9.
24. Lipton JM, Catania A. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol Today. 1997; 18(3): 140-5.
25. Lipton JM. Modulation of host defense by the neuropeptide alpha- MSH. Yale J Biol Med 1990; 63(2): 173-82.
26. Martin LW, Catania A, Hiltz ME, Lipton JM. Neuropeptide alpha- MSH antagonizes IL-6- and TNF-induced fever. Peptides 1991; 12(2): 297-9.
27. Chiao H, Foster S, Thomas R, Lipton J, Star RA. Alphamelanocyte- stimulating hormone reduces endotoxin-induced liver inflammation. J Clin Invest 1996; 97(9): 2038-44.
28. Rajora N, Ceriani G, Catania A, Star RA, Murphy MT, Lipton JM. alpha-MSH production, receptors, and influence on neopterin in a human monocyte/macrophage cell line. J Leukoc Biol 1996; 59(2): 248-53.
29. Star RA, Rajora N, Huang J, Stock RC, Catania A, Lipton JM. Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone. Proc Natl Acad Sci U S A 1995; 92(17): 8016-20.
30. O'Donohue TL, Dorsa DM. The opiomelanotropinergic neuronal and endocrine systems. Peptides 1982; 3(3): 353-95.
31. Chakraborty AK, Funasaka Y, Slominski A, et al. Production and release of proopiomelanocortin (POMC) derived peptides by human melanocytes and keratinocytes in culture: regulation by ultraviolet B. Biochim Biophys Acta 1996; 1313(2): 130-8.
32. Ortego J, Wollmann G, Coca-Prados M. Differential regulation of gene expression of neurotensin and prohormone convertases PC1 and PC2 in the bovine ocular ciliary epithelium: possible implications on neurotensin processing. Neurosci Lett 2002; 333(1): 49-53.
33. Taylor AW, Streilein JW, Cousins SW. Alpha-melanocytestimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon. Neuroimmunomodulation 1994; 1(3): 188-94.
34. McMenamin PG, Holthouse I, Holt PG. Class II major histocompatibility complex (Ia) antigen-bearing dendritic cells within the iris and ciliary body of the rat eye: distribution, phenotype and relation to retinal microglia. Immunology 1992; 77(3): 385-93.
35. Flugel C, Kinne RW, Streilein, JW, Lutjen-Drecoll E. Distinctive distribution of HLA class II presenting and bone marrow derived cells in the anterior segment of human eyes. Curr Eye Res 1992 1992; 11: 1173-83.
36. Streilein JW, Toews GB, Bergstresser PR. Corneal allografts fail to express Ia antigens. Nature 1979; 282(5736): 326-7.
37. Hamrah P, Zhang Q, Liu Y, Dana MR. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest Ophthalmol Vis Sci 2002; 43(3): 639-46.
38. Kuffova L, Netukova M, Duncan L, Porter A, Stockinger B, Forrester JV. Cross presentation of antigen on MHC class II via the draining lymph node after corneal transplantation in mice. J Immunol 2008; 180(3): 1353-61.
39. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
40. Dupont PJ, Warrens AN. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation. Immunology 2007; 120(1): 133-9.
41. Ferguson TA, Griffith TS. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem Immunol Allergy 2007; 92: 140-54.
42. Sugita S, Usui Y, Horie S, et al. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions. Invest Ophthalmol Vis Sci 2009; 50(6): 2862-70.
43. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-48.
44. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
45. Chen L, Sham CW, Chan AM, et al. Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells. Invest Ophthalmol Vis Sci 2009; 50(10): 4941-8.
46. Carter LL, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. European Journal of Immunology 2002; 32: 634-43.
47. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19(7): 813-24.
48. Schreiner B, Bailey SL, Shin T, Chen L, Miller SD. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. Eur J Immunol 2008; 38(10): 2706-17.
49. Hori J, Wang M, Miyashita M, Tanemoto K, Takahashi H, Takemori T, et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol 2006; 177(9): 5928-35.
50. El Annan J, Goyal S, Zhang Q, Freeman G, Sharpe A, Dana R. Programmed Death-Ligand 1 (PD-L1) Regulates T cell Chemotaxis in Dry Eye-Associated Corneal Inflammation. Invest Ophthalmol Vis Sci 2009; 51(7): 3418-23.
51. Usui Y, Okunuki Y, Hattori T, et al. Functional expression of B7H1 on retinal pigment epithelial cells. Exp Eye Res 2008; 86(1): 52-9.
52. Zamiri P, Sugita S, Streilein JW. Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. Chem Immunol Allergy 2007; 92: 86-93.
53. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunol 2001; 2: 261-8.
54. Freeman G, Long A, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-34.
55. Yang W, Li H, Chen PW, et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci 2009; 50(1): 273-80.
56. Gorczynski RM, Chen Z, He W, et al. Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 2009; 183(3): 1560-8.
57. Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002; 23(6): 285-90.
58. Dick AD, Carter D, Robertson M, et al. Control of myeloid activity during retinal inflammation. J Leukoc Biol 2003; 74(2): 161-6.
59. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Threedimensional segregation of supramolecular activation clusters in T cells. Nature 1998; 395(6697): 82-6.
60. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999; 285(5425): 221-7.
61. Robertson MJ, Erwig LP, Liversidge J, Forrester JV, Rees AJ, Dick AD. Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis. Invest Ophthalmol Vis Sci 2002; 43(7): 2250-7.
62. Copland DA, Calder CJ, Raveney BJ, et al. Monoclonal antibodymediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol 2007; 171(2): 580-8.
63. Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 2002; 161(5): 1669-77.
64. Wilbanks GA, Streilein JW. Fluids from immune privileged sites endow macrophages with the capacity to induce antigen-specific immune deviation via a mechanism involving transforming growth factor-beta. Eur J Immunol 1992; 22: 1031-6.
65. Namba K, Kitaichi N, Nishida T, Taylor AW. Induction of regulatory T cells by the immunomodulating cytokines alphamelanocyte- stimulating hormone and transforming growth factorbeta2. J Leukoc Biol 2002; 72(5): 946-52.
66. Nishida T, Taylor AW. Specific aqueous humor factors induce activation of regulatory T cells. Invest Ophthalmol Vis Sci 1999; 40(10): 2268-74.
67. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med 1999; 5(3): 292-7.
68. Sugita S, Horie S, Nakamura O, et al. Retinal pigment epitheliumderived CTLA-2alpha induces TGFbeta-producing T regulatory cells. J Immunol 2008; 181(11): 7525-36.
69. Sugita S, Streilein JW. Iris pigment epithelium expressing CD86 (B7-2) directly suppresses T cell activation in vitro via binding to cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2003; 198(1): 161-71.
70. Liversidge J, McKay D, Mullen G, Forrester JV. Retinal pigment epithelial cells modulate lymphocyte function at the blood-retina barrier by autocrine PGE2 and membrane-bound mechanisms. Cell Immunol 1993; 149(2): 315-30.
71. Sugita S, Futagami Y, Smith SB, Naggar H, Mochizuki M. Retinal and ciliary body pigment epithelium suppress activation of T lymphocytes via transforming growth factor beta. Exp Eye Res 2006; 83(6): 1459-71.
72. Miyajima-Uchida H, Hayashi H, Beppu R, Kuroki M, Fukami M, Arakawa F, et al. Production and accumulation of thrombospondin-1 in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2000; 41(2): 561-7.
73. Sugita S, Ng TF, Schwartzkopff J, Streilein JW. CTLA-4+CD8+ T cells that encounter B7-2+ iris pigment epithelial cells express their own B7-2 to achieve global suppression of T cell activation. J Immunol. 2004; 172(7): 4184-94.
74. Sugita S, Ng TF, Lucas PJ, Gress RE, Streilein JW. B7+ iris pigment epithelium induce CD8+ T regulatory cells; both suppress CTLA-4+ T cells. J Immunol 2006; 176(1): 118-27.
75. Sugita S, Keino H, Futagami Y, Takase H, Mochizuki M, Stein- Streilein J, et al. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells. Invest Ophthalmol Vis Sci 2006; 47(12): 5376-84.
76. Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW. Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci 2005; 46(3): 908-19.
77. Gregerson DS, Heuss ND, Lew KL, McPherson SW, Ferrington DA. Interaction of retinal pigmented epithelial cells and CD4 T cells leads to T-cell anergy. Invest Ophthalmol Vis Sci 2007; 48(10): 4654-63.
78. Villasenor J, Benoist C, Mathis D. AIRE and APECED: molecular insights into an autoimmune disease. Immunol Rev 2005; 204: 156-64.
79. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001; 182: 58-67.
80. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nature Rev Immunol 2003; 3: 199-210.
81. Jiang H, Kashleva H, Xu LX, et al. T cell vaccination induces T cell receptor Vbeta-specific Qa-1-restricted regulatory CD8(+) T cells. Proceedings of the National Academy of Sciences of the United States of America 1998; 95(8): 4533-7.
82. Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol 2004; 5(5): 516-23.
83. Niederkorn JY. The induction of anterior chamber-associated immune deviation. Chem Immunol Allergy 2007; 92: 27-35.
84. Stein-Streilein J. Immune regulation and the eye. Trends Immunol 2008; 29(11): 503-86.
85. Stein-Streilein J, Taylor AW. An eye's view of T regulatory cells. J Leukoc Biol 2007; 81(3): 593-8.
86. Keino H, Takeuchi M, Kezuka T, et al. Induction of eye-derived tolerance does not depend on naturally occurring CD4+CD25+ T regulatory cells. Invest Ophthalmol Vis Sci 2006; 47(3): 1047-55.
87. Keino H, Masli S, Sasaki S, Streilein JW, Stein-Streilein J. CD8* T regulatory cells use a novel genetic program that includes CD103 to suppress Th1 immunity in eye-derived tolerance. Invest Ohthalmol Vis Sci 2006; 47: 1533-43.
88. Gregerson DS, Heuss ND, Lehmann U, McPherson SW. Peripheral induction of tolerance by retinal antigen expression. J Immunol 2009; 183(2): 814-22.
89. Mo JS, Streilein JW. Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS. Eur J Immunol 2001; 31(12): 3806-15.
90. Ohta K, Yamagami S, Taylor AW, Streilein JW. IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxininduced uveitis. Invest Ophthalmol Vis Sci 2000; 41(9): 2591-9.
91. Ohta K, Wiggert B, Taylor AW, Streilein JW. Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci 1999; 40(9): 2010-8.
92. Qiao H, Lucas K, Stein-Streilein J. Retinal laser burn disrupts immune privilege in the eye. Am J Pathol 2009; 174(2): 414-22.
93. Freidlin J, Pak J, Tessler HH, Putterman AM, Goldstein DA. Sympathetic Ophthalmia After Injury in the Iraq War. Ophthal Plast Reconstr Surg 2006; 22(2): 133-4.
94. Damico FM, Kiss S, Young LH. Sympathetic ophthalmia. Semin Ophthalmol 2005; 20(3): 191-7.
95. Subedi S. Sympathetic ophthalmia: a blinding complication of ocular injury. JNMA J Nepal Med Assoc 2005; 44(158): 57-9.
96. Taylor AW. Neuropeptides, aqueous humor, and ocular immune privilege. In: Troger J, Kieslbach G, Bechrakis N, Eds. Neuropeptides in the Eye. Kerala, India 2009. pp. 79-91.
97. Ferguson TA, Hayashi JD, Kaplan HJ. Regulation of the systemic immune response by visible light and the eye. Faseb J 1988; 2(14): 3017-21.
98. Zhang Y, Berger A, Milne CD, Paige CJ. Tachykinins in the immune system. Curr Drug Targets. 2006; 7(8): 1011-20.
99. Maggi CA. The effects of tachykinins on inflammatory and immune cells. Regul Pept 1997; 70(2-3): 75-90.
100. Mignini F, Streccioni V, Amenta F. Autonomic innervation of immune organs and neuroimmune modulation. Auton Autacoid Pharmacol 2003; 23(1): 1-25.
101. Steinman RM, Bonifaz L, Fujii S, Liu K, Bonnyay D, Yamazaki S, et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv Exp Med Biol 2005; 560: 83-97.
102. Pascual DW. The role of tachykinins on bacterial infections. Front Biosci 2004; 9: 3209-17.
103. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201(2): 167-80.
104. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988; 241(4870): 1218-21.
105. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441(7090): 235-8.
106. Wahl SM, Wen J, Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev 2006; 213: 213-27.
107. Taylor AW. Ocular immune privilege. Eye 2009; 23: 1885-9.
108. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441(7090): 231-4.
109. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24(2): 179-89.
110. Mucida D, Park Y, Kim G, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317(5835): 256-60.
111. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007; 204(8): 1757-64.
112. Zhang-Hoover J, Stein-Streilein J. Therapies based on principles of ocular immune privilege. Chem Immunol Allergy 2007; 92: 317-27.
113. Zhang-Hoover J, Stein-Streilein J. Tolerogenic APC generate CD8+ T regulatory cells that modulate pulmonary interstitial fibrosis. J Immunol 2004; 172: 178-85.
114. Faunce DE, Terajewicz A, Stein-Streilein J. Cutting edge: In vitrogenerated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J Immunol 2004; 172: 1991-5.
115. Zhang-Hoover J, Finn P, Stein-Streilein J. Modulation of Ovalbumin-Induced Airway Inflammation and Hyperreactivity by Tolerogenic APC. J Immunol 2005; 175(11): 7117-24.
116. Lin HH, Faunce DE, Stacey M, et al. The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J Exp Med 2005; 201(10): 1615-25.
117. Snelgrove RJ, Goulding J, Didierlaurent AM, et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008; 9(9): 1074-83.